• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Hello Group Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

    12/8/23 8:05:42 AM ET
    $ALGS
    $AULT
    $CDMO
    $CLEU
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Machinery/Components
    Technology
    Get the next $ALGS alert in real time by email

    Shares of Hello Group Inc. (NASDAQ:MOMO) jumped in pre-market trading after reporting results for the third quarter.

    The company said net revenues decreased by 5.9% year-over-year to RMB3,042.8 million ($417.1 million) during the third quarter. Non-GAAP diluted net income per ADS rose to RMB3.05 (US$0.42) from RMB2.60 in the year-ago period.

    Hello Group shares rose 8.1% to $7.10 in pre-market trading.

    Here are some other stocks moving in pre-market trading.

    Gainers

    • MBIA Inc. (NYSE:MBI) shares rose 54.8% to $11.43 in pre-market trading after the company announced it declared an extraordinary cash dividend on MBIA common stock of $8.00 per share.
    • Exicure, Inc. (NASDAQ:XCUR) shares gained 53.4% to $0.6597 in pre-market trading after gaining more than 5% on Thursday.
    • FLJ Group Limited (NASDAQ:FLJ) rose 16.7% to $2.31 in pre-market trading after falling over 56% on Thursday.
    • Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) shares rose 11.4% to $0.2198 in pre-market trading after falling 4% on Thursday.
    • Ault Alliance, Inc.(NYSE:AULT) gained 11% to $0.1020 in pre-market trading after falling around 10% on Thursday.
    • Aligos Therapeutics, Inc. (NASDAQ:ALGS) shares climbed 10.5% to $0.7184 in pre-market trading after the company announced it presented clinical data at Hep-DART 2023 from its Phase 1 studies in HBV and NASH.
    • Tharimmune, Inc. (NASDAQ:THAR) gained 9.3% to $0.6620 in pre-market trading after falling over 5% on Thursday.
    • SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) shares surged 8.9% to $1.10 in pre-market trading. SELLAS Life Sciences recently announced positive recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in acute myeloid leukemia.
    • Clean Earth Acquisitions Corp. (NASDAQ:CLIN) shares rose 8.3% to $5.40 in pre-market trading after dipping over 28% on Thursday.

    Losers

    • Cyngn Inc. (NASDAQ:CYN) dipped 29.4% to $0.2823 in pre-market trading. Cyngn shares jumped 64% on Thursday after the company announced the issuance of a new patent, US-11,837,089-B2, for its autonomous vehicle and driving solutions.
    • Golden Heaven Group Holdings Ltd. (NASDAQ:GDHG) shares fell 22% to $1.81 in pre-market trading. Golden Heaven Group shares dipped 89% on Thursday after the company announced that it intends to enter into an operating lease framework agreement with a top-tier Chinese amusement group.
    • Troika Media Group, Inc. (NASDAQ:TRKA) shares fell 21.7% to $0.4210 in pre-market trading. Troika Media Group shares fell around 72% on Thursday after the company announced it filed for Chapter 11.
    • Avid Bioservices, Inc. (NASDAQ:CDMO) shares fell 20.8% to $4.19 in pre-market trading after the company reported weak quarterly results.
    • HashiCorp, Inc. (NASDAQ:HCP) shares fell 20.5% to $19.80 in pre-market trading after the company reported third-quarter financial results.
    • Solid Biosciences Inc. (NASDAQ:SLDB) shares fell 19.5% to $4.63 in pre-market trading after surging 68% on Thursday. The company announced that it received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its next-generation Duchenne muscular dystrophy gene therapy candidate known as SGT-003.
    • China Liberal Education Holdings Limited (NASDAQ:CLEU) fell 18.4% to $0.2203 in pre-market trading after jumping over 38% on Thursday.
    • Hempacco Co., Inc. (NASDAQ:HPCO) fell 17.7% to $0.3985 in pre-market trading. Hempacco shares jumped 44% on Thursday after the company announced it entered into an exclusive Master Distribution Agreement with CBDAY Global.
    • Save Foods, Inc. (NASDAQ:SVFD) fell 16.4% to $2.55 in pre-market trading. Save Foods shares surged around 42% on Thursday after the company highlighted it's targeting the US carbon credit market following the acquisition of majority ownership in the newly-formed Nitrousink Ltd.
    • RH (NYSE:RH) fell 9.4% to $255.01 in pre-market. RH posted an unexpected loss for its third quarter, while sales missed estimates.

     

    Now Read This: Lululemon, Johnson Outdoors And 3 Stocks To Watch Heading Into Friday

    Get the next $ALGS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALGS
    $AULT
    $CDMO
    $CLEU

    CompanyDatePrice TargetRatingAnalyst
    RH
    $RH
    3/25/2026$185.00 → $165.00Market Perform
    Telsey Advisory Group
    Solid Biosciences Inc.
    $SLDB
    3/20/2026$26.00Buy
    Guggenheim
    Aligos Therapeutics Inc.
    $ALGS
    3/19/2026$48.00Buy
    Jefferies
    RH
    $RH
    12/12/2025$165.00Buy → Hold
    Stifel
    RH
    $RH
    12/12/2025$220.00 → $185.00Market Perform
    Telsey Advisory Group
    Solid Biosciences Inc.
    $SLDB
    12/4/2025$16.00Buy
    Needham
    RH
    $RH
    10/2/2025Outperform → Mkt Perform
    William Blair
    RH
    $RH
    9/12/2025$220.00Outperform → Market Perform
    Telsey Advisory Group
    More analyst ratings

    $ALGS
    $AULT
    $CDMO
    $CLEU
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

    Submission status for RHODES PHARMS's drug DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (ORIG-1) with active ingredient AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE has changed to 'Approval' on 01/13/2021. Application Category: ANDA, Application Number: 213111, Application Classification:

    1/18/21 5:24:40 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

    Submission status for RHODES PHARMS's drug DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (ORIG-1) with active ingredient AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE has changed to 'Approval' on 01/13/2021. Application Category: ANDA, Application Number: 213111, Application Classification:

    1/18/21 5:24:40 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

    Submission status for RHODES PHARMS's drug DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE (ORIG-1) with active ingredient AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE has changed to 'Approval' on 01/15/2021. Application Category: ANDA, Application Number: 213111, Application Classification:

    1/15/21 11:16:15 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    $ALGS
    $AULT
    $CDMO
    $CLEU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Telsey Advisory Group reiterated coverage on RH with a new price target

    Telsey Advisory Group reiterated coverage of RH with a rating of Market Perform and set a new price target of $165.00 from $185.00 previously

    3/25/26 8:14:41 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    Guggenheim initiated coverage on Solid Biosciences with a new price target

    Guggenheim initiated coverage of Solid Biosciences with a rating of Buy and set a new price target of $26.00

    3/20/26 8:37:32 AM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jefferies resumed coverage on Aligos Therapeutics with a new price target

    Jefferies resumed coverage of Aligos Therapeutics with a rating of Buy and set a new price target of $48.00

    3/19/26 8:25:43 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    $AULT
    $CDMO
    $CLEU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Tan Kevin

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    4/21/26 4:05:04 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Herzich Paul

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    4/21/26 4:05:05 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Brooks Gabriel

    4 - Solid Biosciences Inc. (0001707502) (Issuer)

    4/21/26 4:05:08 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    $AULT
    $CDMO
    $CLEU
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by SELLAS Life Sciences Group Inc.

    SCHEDULE 13G/A - SELLAS Life Sciences Group, Inc. (0001390478) (Subject)

    4/24/26 4:11:56 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Sonoma Pharmaceuticals Inc.

    EFFECT - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)

    4/24/26 12:15:24 AM ET
    $SNOA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by SELLAS Life Sciences Group Inc.

    DEFA14A - SELLAS Life Sciences Group, Inc. (0001390478) (Filer)

    4/23/26 4:10:13 PM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALGS
    $AULT
    $CDMO
    $CLEU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company")), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 10,700 shares of the Company's stock (the "Inducement Grant") to newly hired employees on April 22, 2026 (the "Grant Date"), in connection with the commencement of employment. The Inducement Grants were granted pursuant to Aligos' 2024 Inducement Plan (the "Plan") as an induceme

    4/24/26 8:00:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

    CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. The collaboration will focus on evaluating combination strategies involving Burixafor (GPC-100) in indications including sickle cell disease (SCD), acute myeloid leukemia (AML), and solid tumors. Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation and translational research, while Exicure will provide Burixafor and lead clinical and r

    4/22/26 7:54:21 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

    Aligos to receive an upfront payment of $25M USDUp to $420M USD in clinical, regulatory, and sales milestones along with tiered, high single-digit royaltiesAmoytop to fund its development program in Greater ChinaAmoytop is a leading Chinese pharmaceutical company with commercially approved therapeutics, including PEGBING®, to treat chronic HBV infection SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it has entered into an exclusive license agreement to develo

    4/16/26 6:00:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGS
    $AULT
    $CDMO
    $CLEU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kalin Katherine Bach bought $100,806 worth of shares (63,400 units at $1.59), increasing direct ownership by 155% to 104,400 units (SEC Form 4)

    4 - SELLAS Life Sciences Group, Inc. (0001390478) (Issuer)

    11/21/25 8:45:10 AM ET
    $SLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chairman Gravitas Capital Lp bought $500,000 worth of shares (337,838 units at $1.48), increasing direct ownership by 86% to 732,424 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 9:29:23 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Parikh Sanam bought $1,450 worth of shares (1,000 units at $1.45), increasing direct ownership by 130% to 1,770 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 7:34:56 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALGS
    $AULT
    $CDMO
    $CLEU
    Leadership Updates

    Live Leadership Updates

    View All

    RH Announces the Appointment of Veronica Schnitzius as President, Chief Manufacturing & Sourcing Officer

    RH (NYSE:RH) announced today that Veronica Schnitzius is joining the Company as President, Chief Manufacturing & Sourcing Officer. Veronica will lead RH's efforts to build a global manufacturing platform that combines owned and operated, joint-ventured, and outsourced manufacturing for the Company's core furniture business, which represents 80% of RH brand revenues. The strategy will emulate the vertically integrated model of many of the world's largest and most profitable luxury brands that have a high level of control over the manufacturing, quality and capacity of their core business. Mrs. Schnitzius joins RH after a distinguished 24-year career at American Leather, a leading U.S. br

    3/27/26 8:00:00 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    RH Announces the Appointment of David Stanchak as Chief Real Estate and Transformation Officer

    RH (NYSE:RH) today announced that David Stanchak has returned to the Company as Chief Real Estate and Transformation Officer. Mr. Stanchak has resumed his role leading the Company's Global Real Estate Expansion and North American Gallery Transformation, a position he held from May 2015 through May 2021. Mr. Stanchak will also be leading efforts to monetize the Company's significant portfolio of real estate assets in the United States and Europe. RH Chairman and Chief Executive Officer, Gary Friedman commented, "We are thrilled Dave is rejoining Team RH. His leadership expanding our Gallery platform globally, transforming our legacy stores into Design Galleries with integrated Restaurant

    3/26/26 5:49:00 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    Cyngn Adds Former Lyft Exec, Ran Makavy, to Board

    Mr. Makavy led growth at Lyft and later ran its core platform through the 2019 IPO. He also founded Snaptu, which was acquired by Facebook in 2011.MOUNTAIN VIEW, Calif., Feb. 25, 2026 /PRNewswire/ -- Cyngn (NASDAQ:CYN) today announced the appointment of Ran Makavy to its Board of Directors. He brings senior growth and platform leadership experience from Lyft and Facebook, where he helped scale large technology businesses through high-growth phases. At Lyft, Makavy built the growth team which was responsible for getting more drivers and riders to use Lyft and getting them to use

    2/25/26 7:05:00 AM ET
    $CYN
    EDP Services
    Technology

    $ALGS
    $AULT
    $CDMO
    $CLEU
    Financials

    Live finance-specific insights

    View All

    RH to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 31, 2026

    RH (NYSE:RH) today announced that it will report financial results for the fourth quarter and fiscal year 2025 ended January 31, 2026, on Tuesday, March 31, 2026, after market close. RH's fourth quarter and fiscal year 2025 financial results will include a video presentation from Gary Friedman, RH Chairman and Chief Executive Officer, highlighting the Company's continued evolution and recent performance. The video presentation will be posted to the Company's investor relations website at ir.rh.com. RH leadership will host a live webcast of the video presentation followed by Q&A at 2:00 pm Pacific Time (5:00 pm Eastern Time) on March 31, 2026, at ir.rh.com. A replay will also be available

    3/26/26 4:05:00 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    Exicure, Inc. Reports Full Year 2025 Financial Results

    REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position: Cash and cash equivalents were $3.7 million as of December 31, 2025, compared to $12.5 million as of December 31, 2024. Our current liquidity may not be sufficient to fund operations for the next 12 months. Additional financing will be required to support ongoing operations, continue the exploration of strategic alternatives, and pursue any alternatives that we identify. Research and Development (R&D) Expense: Research and development expenses were $3.3 million for the ye

    3/25/26 4:18:31 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hello Group Inc. Announces Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2025

    BEIJING, March 18, 2026 /PRNewswire/ -- Hello Group Inc. (NASDAQ:MOMO) ("Hello Group" or the "Company"), a leading player in Asia's online social networking space, today announced its unaudited financial results for the fourth quarter and the full year ended December 31, 2025.   Fourth Quarter of 2025 HighlightsNet revenues decreased by 2.3% year over year to RMB2,575.8 million (US$368.3 million*) in the fourth quarter of 2025.Net revenues from overseas increased by 70.3% year over year to RMB608.2 million (US$87.0 million) in the fourth quarter of 2025.Net income attributable to Hello Group Inc. was RMB237.3 million (US$33.9 million) in the fourth quarter of 2025, compared to RMB187.2 milli

    3/18/26 3:05:00 AM ET
    $MOMO
    Computer Software: Prepackaged Software
    Technology

    $ALGS
    $AULT
    $CDMO
    $CLEU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avid Bioservices Inc.

    SC 13G - Avid Bioservices, Inc. (0000704562) (Subject)

    12/13/24 10:53:25 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Exicure Inc.

    SC 13D - EXICURE, INC. (0001698530) (Subject)

    11/29/24 5:51:28 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Solid Biosciences Inc.

    SC 13D/A - Solid Biosciences Inc. (0001707502) (Subject)

    11/14/24 7:59:25 PM ET
    $SLDB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care